In Treatment of Bone Metastases, Dexamethasone Reduces RT-Induced Pain Flare

Dexamethasone reduced radiation-induced pain flare after palliative radiotherapy for painful bone metastases.
Dexamethasone reduced radiation-induced pain flare after palliative radiotherapy for painful bone metastases.

Dexamethasone reduced radiation-induced pain flare after palliative radiotherapy for painful bone metastases, a new study published online ahead of print in the journal The Lancet Oncology has shown.1

Because dexamethasone has demonstrated potential as a prophylactic agent for pain flare occurring after palliative radiotherapy, researchers sought to compare the efficacy of dexamethasone with that of placebo in reducing the incidence of pain flare.

For the multicenter, double-blind, placebo-controlled, phase III trial, researchers enrolled 298 patients with a non-hematologic malignancy and pain in the area or areas of bone metastases.

Participants were randomly assigned 1:1 to receive either dexamethasone 8 mg orally or placebo at least 1 hour prior to the start of radiation, which was given as a single 8-Gy dose to bone metastases on day 0, and then each day for 4 days after radiation.

Results showed that 26% of patients in the dexamethasone group and 35% of those in the placebo group experienced a pain flare, defined as at least a 2-point increase on a 0 to 10 worst pain scale with no reduction in analgesic intake or a 25% or greater increase in analgesic intake with no reduction in worst pain score from days 0 to 10.

In regard to safety, the most common adverse events were bone pain, fatigue, constipation, and nausea. Researchers found that three grade 3 or 4 hyperglycemic events occurred in the dexamethasone group.

Reference

  1. Chow E, Meyer RM, Ding K, et al. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial [published online ahead of print October 18, 2015]. Lancet Oncol. doi:10.1016/S1470-2045(15)00199-0.
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs